MedPath

Evaxion Biotech

Evaxion Biotech logo
🇩🇰Denmark
Ownership
Public
Established
2008-01-01
Employees
49
Market Cap
-
Website
http://www.evaxion-biotech.com
Introduction

Evaxion Biotech A/S engages in the discovery and development of immunotherapies for cancer and infectious diseases. Its technologies include the immuno-oncology platform PIONEER, the bacterial disease platform EDEN, the viral disease platform RAVEN, and the proprietary AI platform technology ObsERV. The company was founded by Niels Iversen M?ller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.

Clinical Trials

3

Active:1
Completed:0

Trial Phases

2 Phases

Phase 1:2
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (66.7%)
Phase 2
1 (33.3%)

A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma

Phase 2
Recruiting
Conditions
Melanoma Stage III
Melanoma Stage IV
Interventions
First Posted Date
2022-04-04
Last Posted Date
2023-09-28
Lead Sponsor
Evaxion Biotech A/S
Target Recruit Count
90
Registration Number
NCT05309421
Locations
🇦🇺

Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia

🇦🇺

Ballarat Health Services (Grampians Health), Ballarat Central, Victoria, Australia

🇦🇺

One Clinical Research, Nedlands, Western Australia, Australia

and more 1 locations

Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1

Phase 1
Terminated
Conditions
Melanoma Stage IV
Melanoma Stage III
Interventions
Drug: EVX-02A OR EVX-02B
First Posted Date
2020-07-02
Last Posted Date
2024-02-21
Lead Sponsor
Evaxion Biotech A/S
Target Recruit Count
15
Registration Number
NCT04455503
Locations
🇦🇺

Liverpool Hospital, Goulburn, New South Wales, Australia

🇦🇺

Flinders Medical Centre, Adelaide, South Australia, Australia

🇦🇺

Monash Medical Centre, Clayton, Victoria, Australia

and more 3 locations

News

ExpreS2ion Biotech Advances to Clinical Phase with HER2 Breast Cancer Vaccine, Reports Strong Q4 2024 Progress

• ExpreS2ion Biotech secured crucial approval for Phase I clinical trial of ES2B-C001, their novel HER2-expressing breast cancer therapeutic vaccine, marking their entry into clinical development. • The company's collaboration with University of Oxford yielded positive Phase 2b malaria vaccine results, published in The Lancet Infectious Diseases, showing promise in meeting WHO's 75% efficacy goal. • ExpreS2ion strengthened its financial position through successful TO 10 warrants exercise, raising approximately SEK 10 million, while maintaining a cash balance of SEK 81.5 million by end of 2024.

Evaxion's AI-Immunology Platform Validated Across Multiple Clinical Trials

Evaxion Biotech's AI-Immunology™ platform demonstrates strong ability to select clinically relevant vaccine targets across three clinical trials.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.